Tags

Type your tag names separated by a space and hit enter

Neuraminidase inhibitors for the treatment and prevention of influenza.
Expert Opin Pharmacother 2002; 3(2):103-12EO

Abstract

The impact of influenza virus infection is estimated to run into billions of dollars worldwide. Vaccination plays a key role in prevention; however, vaccines do not provide complete protection against influenza due to the constant mutation of the virus responsible. Unlike amantadine and rimantadine, which are only effective against influenza A, the new neuraminidase inhibitors zanamivir (Relenza), GlaxoSmithKline) and oseltamivir (Tamiflu), Gilead/Roche) are potent and specific inhibitors of influenza types A and B and have minimal side effects. The greatest benefit is derived if treatment commences as soon as possible after symptoms develop. In order for these inhibitors to have a significant impact on the disease, clinicians and the general public need to be made more aware of the symptoms of influenza and the availability of these new drugs.

Authors+Show Affiliations

CSIRO Division of Health Sciences and Nutrition, 343 Royal Parade, Parkville, Australia 3052. jennifer.mckimm-breschkin@csiro.au

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11829724

Citation

McKimm-Breschkin, Jennifer L.. "Neuraminidase Inhibitors for the Treatment and Prevention of Influenza." Expert Opinion On Pharmacotherapy, vol. 3, no. 2, 2002, pp. 103-12.
McKimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin Pharmacother. 2002;3(2):103-12.
McKimm-Breschkin, J. L. (2002). Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opinion On Pharmacotherapy, 3(2), pp. 103-12.
McKimm-Breschkin JL. Neuraminidase Inhibitors for the Treatment and Prevention of Influenza. Expert Opin Pharmacother. 2002;3(2):103-12. PubMed PMID: 11829724.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuraminidase inhibitors for the treatment and prevention of influenza. A1 - McKimm-Breschkin,Jennifer L, PY - 2002/2/7/pubmed PY - 2002/7/26/medline PY - 2002/2/7/entrez SP - 103 EP - 12 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 3 IS - 2 N2 - The impact of influenza virus infection is estimated to run into billions of dollars worldwide. Vaccination plays a key role in prevention; however, vaccines do not provide complete protection against influenza due to the constant mutation of the virus responsible. Unlike amantadine and rimantadine, which are only effective against influenza A, the new neuraminidase inhibitors zanamivir (Relenza), GlaxoSmithKline) and oseltamivir (Tamiflu), Gilead/Roche) are potent and specific inhibitors of influenza types A and B and have minimal side effects. The greatest benefit is derived if treatment commences as soon as possible after symptoms develop. In order for these inhibitors to have a significant impact on the disease, clinicians and the general public need to be made more aware of the symptoms of influenza and the availability of these new drugs. SN - 1465-6566 UR - https://www.unboundmedicine.com/medline/citation/11829724/Neuraminidase_inhibitors_for_the_treatment_and_prevention_of_influenza_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.3.2.103 DB - PRIME DP - Unbound Medicine ER -